| A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007) (NCT07300085) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2025-11-08 |
| A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07) (NCT07225959) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2025-10-29 |
| A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza (NCT07159763) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2025-09-25 |
| Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications (NCT06609460) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2024-09-20 |
| Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects (NCT05619536) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2022-10-18 |
| The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults (NCT05523089) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2022-09-09 |
| Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects (NCT05285137) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2022-03-14 |
| Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis (NCT03667690) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2018-10-07 |
| Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization (NCT02888197) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-08-16 |
| CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension (NCT02734862) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-07-26 |
| RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections (NCT02733432) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-06-08 |
| An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects (NCT02551549) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2015-09-01 |
| A Single Ascending Dose Study of CD101 IV in Healthy Subjects (NCT02516904) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2015-07-01 |